

# Global Neurodegenerative Diseases Drugs Market Report and Forecast 2023-2028

Market Report | 2023-09-27 | 188 pages | EMR Inc.

#### **AVAILABLE LICENSES:**

- Single User License \$2999.00
- Five User License \$3999.00
- Corporate License \$4999.00

## Report description:

Global Neurodegenerative Diseases Drugs Market Report and Forecast 2023-2028 Market Outlook

According to the report by Expert Market Research (EMR), the global neurodegenerative diseases drugs market reached a value of USD 41.73 billion in 2022. Aided by the expanding geriatric population and the mounting prevalence of neurodegenerative disorders, the market is projected to further grow at a CAGR of 7.10% between 2023 and 2028.

Neurodegenerative diseases are conditions characterised by the progressive degeneration or death of nerve cells, also known as neurons. Notable illnesses under this category include Alzheimer's disease, Parkinson's disease, and Huntington's disease, among others. Drugs designed to treat these ailments primarily aim to alleviate symptoms, decelerate disease progression, and improve the patient's quality of life. With the complexity of the human brain and the diseases that afflict it, research in this realm has been both intricate and intensive.

As per the global neurodegenerative diseases drugs market analysis, the market is predominantly influenced by the upsurge in the elderly population worldwide. Ageing remains a principal risk factor for many neurodegenerative disorders. As the global population experiences increased longevity, the occurrence of these diseases has inevitably risen, leading to heightened demand for effective therapeutic interventions.

Simultaneously, the intensifying awareness about neurodegenerative diseases and their early symptoms has played a pivotal role in boosting the demand for related drugs. Public health initiatives and campaigns have illuminated the signs and consequences of these conditions, fostering early detection and subsequent treatment. This proactive approach to neurodegenerative diseases translates to increased demand for therapeutic drugs.

Moreover, innovative breakthroughs and persistent research and development activities in the pharmaceutical sector substantially propel the neurodegenerative diseases drugs market demand. New drug discoveries, combined with advanced therapeutic techniques, promise better management of these diseases, furthering the appeal of the market for neurodegenerative diseases drugs. Collaborations between pharma giants and biotech startups have also hastened drug discovery processes, leading to more robust pipelines and quicker drug approvals.

Beyond these factors, the neurodegenerative diseases drugs market growth is invigorated by technological advancements in diagnostic methodologies. Enhanced imaging technologies, genetic testing, and biomarker analysis facilitate the early and

accurate diagnosis of neurodegenerative diseases. An early diagnosis often necessitates timely drug interventions, thereby indirectly bolstering the demand for neurodegenerative diseases drugs.

Market Segmentation

The market can be divided based on drug class, disease indication, route of administration, end-user, and region.

Market Breakup by Drug Class

- -∏Immunomodulator
- -□Interferons
- -□Decarboxylase Inhibitors
- Dopamine Agonists
- Others

Market Breakup by Disease Indication

- -∏Multiple Sclerosis
- -□Parkinson's Disease
- Alzheimer's Disease
- -□Spinal Muscular Atrophy (SMA)
- -∏Others

Market Breakup by Route of Administration

- -[]Oral
- -□Injection
- Transdermal

Market Breakup by End-User

- Hospital Pharmacy
- -□Online

Market Breakup by Region

- North America
- -□Europe
- -∏Asia Pacific
- -[]Latin America
- -∏Middle East and Africa

Competitive Landscape

The EMR report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the global neurodegenerative diseases drugs market. Some of the major players explored in the report by Expert Market Research are as follows:

- -□Pfizer, Inc.
- -□Merck KGaA
- -□Novartis AG
- -□Acadia Pharmaceuticals Inc.
- -□Teva Pharmaceutical Industries Ltd.
- -∏F. Hoffmann-La Roche Ltd
- -□Others

About Us

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Our high-quality, data-driven analyses provide the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

can ensure your organisation remains agile, proactive, and poised for success in today's competitive market.

Don't miss the opportunity to elevate your business intelligence and fortify your strategic planning. Secure your organisation's future success by acquiring one of our Expert Market Research reports today.

\*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

### **Table of Contents:**

- 1 Preface
- 2 Report Coverage Key Segmentation and Scope
- 3 Report Description
  - 3.1 Market Definition and Outlook
  - 3.2 Properties and Applications
  - 3.3 Market Analysis
  - 3.4 Key Players
- 4 Key Assumptions
- 5 Executive Summary
  - 5.1 Overview
  - 5.2 Key Drivers
  - 5.3 Key Developments
  - 5.4 Competitive Structure
  - 5.5 Key Industrial Trends
- 6 Market Snapshot
  - 6.1 Global
  - 6.2 Region
- 7 Industry Opportunities and Challenges
- 8 Global Neurodegenerative Diseases Drugs Market Analysis
  - 8.1 Key Industry Highlights
  - 8.2 Global Neurodegenerative Diseases Drugs Historical Market (2018-2022)
  - 8.3 Global Neurodegenerative Diseases Drugs Market Forecast (2023-2028)
  - 8.4 Global Neurodegenerative Diseases Drugs Market by Drug Class
    - 8.4.1 Immunomodulator
      - 8.4.1.1 Market Share
      - 8.4.1.2 Historical Trend (2018-2022)
      - 8.4.1.3 Forecast Trend (2023-2028)
    - 8.4.2 Interferons
      - 8.4.2.1 Market Share
      - 8.4.2.2 Historical Trend (2018-2022)
      - 8.4.2.3 Forecast Trend (2023-2028)
    - 8.4.3 Decarboxylase Inhibitors
      - 8.4.3.1 Market Share
      - 8.4.3.2 Historical Trend (2018-2022)
      - 8.4.3.3 Forecast Trend (2023-2028)
    - 8.4.4 Dopamine Agonists
      - 8.4.4.1 Market Share
      - 8.4.4.2 Historical Trend (2018-2022)
      - 8.4.4.3 Forecast Trend (2023-2028)

#### 8.4.5 Others

- 8.5 Global Neurodegenerative Diseases Drugs Market by Disease Indication
  - 8.5.1 Multiple Sclerosis
    - 8.5.1.1 Market Share
    - 8.5.1.2 Historical Trend (2018-2022)
    - 8.5.1.3 Forecast Trend (2023-2028)
  - 8.5.2 Parkinson's Disease
    - 8.5.2.1 Market Share
    - 8.5.2.2 Historical Trend (2018-2022)
    - 8.5.2.3 Forecast Trend (2023-2028)
  - 8.5.3 Alzheimer's Disease
    - 8.5.3.1 Market Share
    - 8.5.3.2 Historical Trend (2018-2022)
    - 8.5.3.3 Forecast Trend (2023-2028)
  - 8.5.4 Spinal Muscular Atrophy (SMA)
    - 8.5.4.1 Market Share
    - 8.5.4.2 Historical Trend (2018-2022)
    - 8.5.4.3 Forecast Trend (2023-2028)
  - 8.5.5 Others
- 8.6 Global Neurodegenerative Diseases Drugs Market by Route of Administration
  - 8.6.1 Oral
    - 8.6.1.1 Market Share
    - 8.6.1.2 Historical Trend (2018-2022)
    - 8.6.1.3 Forecast Trend (2023-2028)
  - 8.6.2 Injection
    - 8.6.2.1 Market Share
    - 8.6.2.2 Historical Trend (2018-2022)
    - 8.6.2.3 Forecast Trend (2023-2028)
  - 8.6.3 Transdermal
    - 8.6.3.1 Market Share
    - 8.6.3.2 Historical Trend (2018-2022)
    - 8.6.3.3 Forecast Trend (2023-2028)
- 8.7 Global Neurodegenerative Diseases Drugs Market by End-User
  - 8.7.1 Hospital Pharmacy
    - 8.7.1.1 Market Share
    - 8.7.1.2 Historical Trend (2018-2022)
    - 8.7.1.3 Forecast Trend (2023-2028)
  - 8.7.2 Retail Pharmacy
    - 8.7.2.1 Market Share
    - 8.7.2.2 Historical Trend (2018-2022)
    - 8.7.2.3 Forecast Trend (2023-2028)
  - 8.7.3 Online
    - 8.7.3.1 Market Share
    - 8.7.3.2 Historical Trend (2018-2022)
    - 8.7.3.3 Forecast Trend (2023-2028)
- 8.8 Global Neurodegenerative Diseases Drugs Market by Region
  - 8.8.1 Market Share

# Scotts International. EU Vat number: PL 6772247784

- 8.8.1.1 North America
- 8.8.1.2 Europe
- 8.8.1.3 Asia Pacific
- 8.8.1.4 Latin America
- 8.8.1.5 Middle East and Africa

# 9 Regional Analysis

- 9.1 North America
  - 9.1.1 Historical Trend (2018-2022)
  - 9.1.2 Forecast Trend (2023-2028)
  - 9.1.3 Breakup by Country
    - 9.1.3.1 United States of America
    - 9.1.3.2 Canada
- 9.2 Europe
  - 9.2.1 Historical Trend (2018-2022)
  - 9.2.2 Forecast Trend (2023-2028)
  - 9.2.3 Breakup by Country
    - 9.2.3.1 United Kingdom
    - 9.2.3.2 Germany
    - 9.2.3.3 France
    - 9.2.3.4 Italy
    - 9.2.3.5 Others
- 9.3 Asia Pacific
  - 9.3.1 Historical Trend (2018-2022)
  - 9.3.2 Forecast Trend (2023-2028)
  - 9.3.3 Breakup by Country
    - 9.3.3.1 China
    - 9.3.3.2 Japan
    - 9.3.3.3 India
    - 9.3.3.4 ASEAN
    - 9.3.3.5 Australia
    - 9.3.3.6 Others
- 9.4 Latin America
  - 9.4.1 Historical Trend (2018-2022)
  - 9.4.2 Forecast Trend (2023-2028)
  - 9.4.3 Breakup by Country
    - 9.4.3.1 Brazil
    - 9.4.3.2 Argentina
    - 9.4.3.3 Mexico
    - 9.4.3.4 Others
- 9.5 Middle East and Africa
  - 9.5.1 Historical Trend (2018-2022)
  - 9.5.2 Forecast Trend (2023-2028)
  - 9.5.3 Breakup by Country
    - 9.5.3.1 Saudi Arabia
    - 9.5.3.2 United Arab Emirates
    - 9.5.3.3 Nigeria
    - 9.5.3.4 South Africa

# Scotts International. EU Vat number: PL 6772247784

#### 9.5.3.5 Others

## 10 Market Dynamics

- 10.1 SWOT Analysis
  - 10.1.1 Strengths
  - 10.1.2 Weaknesses
  - 10.1.3 Opportunities
  - 10.1.4 Threats
- 10.2 Porter's Five Forces Analysis
  - 10.2.1 Supplier's Power
  - 10.2.2 Buyer's Power
  - 10.2.3 Threat of New Entrants
  - 10.2.4 Degree of Rivalry
  - 10.2.5 Threat of Substitutes
- 10.3 Key Indicators for Demand
- 10.4 Key Indicators for Price
- 11 Competitive Landscape
  - 11.1 Market Structure
  - 11.2 Company Profiles
    - 11.2.1 Pfizer, Inc.
      - 11.2.1.1 Company Overview
      - 11.2.1.2 Product Portfolio
      - 11.2.1.3 Demographic Reach and Achievements
      - 11.2.1.4 Certifications
    - 11.2.2 Merck KGaA
      - 11.2.2.1 Company Overview
      - 11.2.2.2 Product Portfolio
      - 11.2.2.3 Demographic Reach and Achievements
      - 11.2.2.4 Certifications
    - 11.2.3 Novartis AG
      - 11.2.3.1 Company Overview
      - 11.2.3.2 Product Portfolio
      - 11.2.3.3 Demographic Reach and Achievements
      - 11.2.3.4 Certifications
    - 11.2.4 Acadia Pharmaceuticals Inc.
      - 11.2.4.1 Company Overview
      - 11.2.4.2 Product Portfolio
      - 11.2.4.3 Demographic Reach and Achievements
      - 11.2.4.4 Certifications
    - 11.2.5 Teva Pharmaceutical Industries Ltd.
      - 11.2.5.1 Company Overview
      - 11.2.5.2 Product Portfolio
      - 11.2.5.3 Demographic Reach and Achievements
      - 11.2.5.4 Certifications
    - 11.2.6 F. Hoffmann-La Roche Ltd
      - 11.2.6.1 Company Overview
      - 11.2.6.2 Product Portfolio
      - 11.2.6.3 Demographic Reach and Achievements

Scotts International. EU Vat number: PL 6772247784

#### 11.2.6.4 Certifications

#### 11.2.7 Others

#### 12 Industry Events and Developments

## List of Key Figures and Tables

- Global Neurodegenerative Diseases Drugs Market: Key Industry Highlights, 2018 and 2028
- 2. Global Neurodegenerative Diseases Drugs Historical Market: Breakup by Drug Class (USD Million), 2018-2022
- 3. Global Neurodegenerative Diseases Drugs Market Forecast: Breakup by Drug Class (USD Million), 2023-2028
- 4. Global Neurodegenerative Diseases Drugs Historical Market: Breakup by Disease Indication (USD Million), 2018-2022
- 5. Global Neurodegenerative Diseases Drugs Market Forecast: Breakup by Disease Indication (USD Million), 2023-2028
- 6. Global Neurodegenerative Diseases Drugs Historical Market: Breakup by Route of Administration (USD Million), 2018-2022
- 7. Global Neurodegenerative Diseases Drugs Market Forecast: Breakup by Route of Administration (USD Million), 2023-2028
- 8. Global Neurodegenerative Diseases Drugs Historical Market: Breakup by End-User (USD Million), 2018-2022
- 9. Global Neurodegenerative Diseases Drugs Market Forecast: Breakup by End-User (USD Million), 2023-2028
- 10. Global Neurodegenerative Diseases Drugs Historical Market: Breakup by Region (USD Million), 2018-2022
- 11. Global Neurodegenerative Diseases Drugs Market Forecast: Breakup by Region (USD Million), 2023-2028
- 12. North America Neurodegenerative Diseases Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
- 13. North America Neurodegenerative Diseases Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
- 14. Europe Neurodegenerative Diseases Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
- 15. Europe Neurodegenerative Diseases Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
- 16. Asia Pacific Neurodegenerative Diseases Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
- 17. Asia Pacific Neurodegenerative Diseases Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
- 18. Latin America Neurodegenerative Diseases Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
- 19. Latin America Neurodegenerative Diseases Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
- 20. Middle East and Africa Neurodegenerative Diseases Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
- 21. Middle East and Africa Neurodegenerative Diseases Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
- 22. Global Neurodegenerative Diseases Drugs Market Structure.



Print this form

To place an Order with Scotts International:

# Global Neurodegenerative Diseases Drugs Market Report and Forecast 2023-2028

Market Report | 2023-09-27 | 188 pages | EMR Inc.

| ☐ - Complete the re               | evant blank fields and sign            |                      |            |           |
|-----------------------------------|--|----------------------|------------|-----------|
| <ul><li>Send as a scann</li></ul> | ed email to support@scotts-internation | al.com               |            |           |
| ORDER FORM:                       |  |                      |            |           |
| Select license                    | License                                |                      |            | Price     |
|                                   | Single User License                    |                      |            | \$2999.00 |
|                                   | Five User License                      |                      |            | \$3999.00 |
|                                   | Corporate License                      |                      |            | \$4999.00 |
|                                   |  |                      | VAT        |           |
|                                   |  |                      | Total      |           |
| Email*                            | P                                      | 'hone*               |            |           |
| First Name*                       | L                                      | ast Name*            |            |           |
| Job title*                        |  |                      |            |           |
| Company Name*                     | E                                      | U Vat / Tax ID / NIP | number*    |           |
| Address*                          |  | City*                |            |           |
| Zip Code*                         | (                                      | Country*             |            |           |
|                                   | 0                                      | Oate                 | 2025-05-05 |           |
|                                   | S                                      | iignature            |            |           |
|                                   |  |                      |            | 1         |

Scotts International. EU Vat number: PL 6772247784